Integrated Wealth Concepts LLC grew its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 16.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 288,101 shares of the company's stock after purchasing an additional 41,564 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Roivant Sciences were worth $3,408,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Syon Capital LLC acquired a new position in Roivant Sciences in the fourth quarter valued at $270,000. BlackBarn Capital Partners LP raised its position in shares of Roivant Sciences by 3.1% in the 4th quarter. BlackBarn Capital Partners LP now owns 4,125,000 shares of the company's stock worth $48,799,000 after acquiring an additional 125,000 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Roivant Sciences by 816.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 63,458 shares of the company's stock valued at $751,000 after purchasing an additional 56,534 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Roivant Sciences by 7.4% in the 4th quarter. MetLife Investment Management LLC now owns 242,037 shares of the company's stock valued at $2,863,000 after purchasing an additional 16,717 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Roivant Sciences by 104.4% during the 4th quarter. Marshall Wace LLP now owns 2,946,954 shares of the company's stock valued at $34,862,000 after purchasing an additional 1,505,062 shares in the last quarter. 64.76% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 218,041 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,345,374.98. This trade represents a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,395,541 shares of company stock worth $14,922,538. Insiders own 7.90% of the company's stock.
Roivant Sciences Stock Performance
ROIV stock opened at $11.01 on Friday. The stock's 50 day simple moving average is $10.34 and its 200 day simple moving average is $11.15. The company has a market cap of $7.86 billion, a P/E ratio of -73.40 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Analyst Upgrades and Downgrades
ROIV has been the topic of several recent analyst reports. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 21st.
Get Our Latest Stock Report on Roivant Sciences
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
